RITES Limited (BOM:541556)

Inozyme Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	9,397	525.7	1,140	497.1	1,186
Short-Term Investments	-	200	7,225	7,981	7,071	8,297
Trading Asset Securities	-	-	-	-	259.2	857.7
Cash & Short-Term Investments	9,597	9,597	7,751	9,121	7,827	10,340
Cash Growth	23.29%	23.81%	-15.02%	16.53%	-24.31%	-15.38%
Accounts Receivable	-	7,400	10,522	10,162	7,982	6,711
Other Receivables	-	878.3	1,640	1,789	1,907	1,300
Receivables	-	8,331	12,212	12,005	9,924	8,081
Inventory	-	780.8	49.3	309.1	1,188	2,862
Prepaid Expenses	-	-	75.5	61.4	61.7	51.8
Other Current Assets	-	30,160	25,022	26,824	27,616	26,763
Total Current Assets	-	48,868	45,109	48,320	46,616	48,098
Property, Plant & Equipment	-	6,385	7,033	6,462	6,153	5,959
Long-Term Investments	-	968	1,103	1,049	2,369	1,781
Other Intangible Assets	-	55.7	56.7	67.7	26.1	40.2
Long-Term Deferred Tax Assets	-	206	266.6	311.9	319.1	270.1
Long-Term Deferred Charges	-	-	50.6	38.6	11.7	15.1
Other Long-Term Assets	-	4,580	2,872	3,387	2,642	2,071
Total Assets	-	61,192	56,614	59,723	58,225	58,333
Accounts Payable	-	3,643	2,199	3,021	1,811	2,964
Accrued Expenses	-	-	1,210	1,320	1,364	1,437
Short-Term Debt	-	-	-	-	-	0.7
Current Portion of Long-Term Debt	-	-	-	-	76.7	76.7
Current Portion of Leases	-	24.4	16.2	9	22.7	20
Other Current Liabilities	-	28,224	23,945	25,189	26,858	26,452
Total Current Liabilities	-	31,891	27,370	29,539	30,132	30,950
Long-Term Debt	-	-	-	-	169.8	246.4
Long-Term Leases	-	65.9	63.8	45.2	6.7	21.7
Other Long-Term Liabilities	-	1,743	1,942	2,918	1,943	2,285
Total Liabilities	-	33,699	29,405	32,532	32,279	33,532
Common Stock	-	4,806	2,403	2,403	2,403	2,403
Retained Earnings	-	-	23,532	23,479	22,326	21,359
Comprehensive Income & Other	-	21,596	154.9	156.3	157.7	157.6
Total Common Equity	26,402	26,402	26,090	26,038	24,886	23,920
Minority Interest	-	1,091	1,119	1,153	1,060	881.6
Shareholders' Equity	27,493	27,493	27,209	27,191	25,946	24,801
Total Liabilities & Equity	-	61,192	56,614	59,723	58,225	58,333
Total Debt	90.3	90.3	80	54.2	275.9	365.5
Net Cash (Debt)	9,507	9,507	7,671	9,067	7,551	9,975
Net Cash Growth	23.39%	23.93%	-15.39%	20.07%	-24.30%	-15.07%
Net Cash Per Share	19.81	19.79	15.96	18.86	15.71	20.24
Filing Date Shares Outstanding	479.64	480.83	480.6	480.6	480.6	480.6
Total Common Shares Outstanding	479.64	480.83	480.6	480.6	480.6	480.6
Working Capital	-	16,977	17,740	18,782	16,484	17,148
Book Value Per Share	54.91	54.91	54.29	54.18	51.78	49.77
Tangible Book Value	26,346	26,346	26,033	25,970	24,860	23,880
Tangible Book Value Per Share	54.79	54.79	54.17	54.04	51.73	49.69
Land	-	-	354.4	354.4	353.9	353.9
Buildings	-	-	1,608	1,610	1,533	1,514
Machinery	-	-	7,042	6,732	6,321	5,961
Construction In Progress	-	-	1,737	980.4	581.1	154.9
Leasehold Improvements	-	-	19.6	19.6	19.6	19.6
Order Backlog	-	-	56,900	-	-	-

Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.